Trial Outcomes & Findings for Tranexamic Acid and Blood Clots in Knee Surgery (NCT NCT02867163)
NCT ID: NCT02867163
Last Updated: 2019-05-20
Results Overview
Incidence of deep vein thrombosis diagnosed by ultrasound scan on postoperative day 1
Recruitment status
COMPLETED
Target enrollment
25 participants
Primary outcome timeframe
One day
Results posted on
2019-05-20
Participant Flow
Participant milestones
| Measure |
Knee Replacement Patients Receiving TXA
Patients who receive tranexamic acid during total knee replacement surgery
Tranexamic Acid: Intravenous or local administration of TXA, in any dosage
|
|---|---|
|
Overall Study
STARTED
|
25
|
|
Overall Study
COMPLETED
|
25
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Knee Replacement Patients Receiving TXA
n=25 Participants
Patients who receive tranexamic acid during total knee replacement surgery
Tranexamic Acid: Intravenous or local administration of TXA, in any dosage
|
|---|---|
|
Age, Continuous
|
63 years
STANDARD_DEVIATION 9 • n=25 Participants
|
|
Sex: Female, Male
Female
|
17 Participants
n=25 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=25 Participants
|
|
Region of Enrollment
United States
|
25 participants
n=25 Participants
|
PRIMARY outcome
Timeframe: One dayIncidence of deep vein thrombosis diagnosed by ultrasound scan on postoperative day 1
Outcome measures
| Measure |
Knee Replacement Patients Receiving TXA
n=25 Participants
Patients who receive tranexamic acid during total knee replacement surgery
Tranexamic Acid: Intravenous or local administration of TXA, in any dosage
|
|---|---|
|
Deep Vein Thrombosis
|
2 Participants
|
Adverse Events
Knee Replacement Patients Receiving TXA
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place